Wyeth shareholders approve merger

Wyeth investors have voted to approve Pfizer's proposed $68bn takeover by an overwhelming 98 per cent, according to a preliminary tally

Wyeth investors have voted to approve Pfizer's proposed $68bn takeover by an overwhelming 98 per cent, according to a preliminary tally.

The news follows the recent announcement that the European Commission has approved the deal, subject to Pfizer's pledge to shed certain animal-health assets in Europe. The deal is still subject to clearance by anti-trust regulators in the US.

New York-based Pfizer expects the deal to close by the end of the year.